The Ordinary General Meeting of Shareholders of Red Laboratories, held on Wednesday in the first call, has approved the distribution of a dividend of 0.9351 euros per share which is equivalent to a total maximum of 47.8 million euros. This dividend will be financed by the benefit of exercise 2024, representing a 35% of consolidated profits of the pharmaceutical.
In addition to the approval of the points of the agenda, Rovi confirmed his ‘Guidance’ for this year. The company stressed that this compensation is part of its Value creation strategy for shareholderswhich has been supported by the shareholders.
Since November 2021, Rovi has allocated more than 300 million euros to the execution of repurchase programs of own shares, which has contributed to the increase in the benefit per share and, therefore, to the compensation to the shareholder.
Rovi’s president, Juan López Belmonte-EncinaHe pointed out that the year 2024 was key to establishing the basis of the future of the company, highlighting the strengthening of the capacity in the manufacturing area to third parties. The company aims to multiply its operational income by 2030, standing between 1,145.6 and 1,374.7 million euros.
Growth strategy
The pharmacist has indicated that the support of the Board contributes to the current growth strategy for the long term, within the framework of its forecast to multiply by two-between 1.5 and 1.8 times-the operational income in 2030, placing between 1,145.6 million and 1,374.7 million euros.
Rovi is investing in the expansion of the capacities of his manufacturing business to third parties to address the imbalance between supply and demand at a global level. The manufacturing business to third parties is expected to double your sales to 700 million euros In 2030. Likewise, the company is confident in multiplying its EBITDA before the R&D expenses, reaching the 653 million euros in five years.
By 2025, Rovi projects that his operational income decreases between a 0% y 10% Regarding 2024, when they reached the 763.7 million euros.
Reelections in the Board of Directors
The Board of Directors of Rovi approved the reelections of the President and CEO, Juan López-Belmonte Encina, as well as the vice presidents Javier López-Belmonte Encina and Iván López-Belmonte Encina, as executive counselors for one year. An annual maximum total remuneration was also approved 1.1 million euros For members of the company’s highest governing body this year.